Kymera Therapeutics Financials - Benzinga

Kymera Therapeutics Inc

KYMRNASDAQ

Trade with Public

Trade with Public

$110.77

0.260.24%

最終更新: Sep 30, 9:30 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Kymera Therapeutics Financials

Kymera Therapeutics (KYMR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share

Benzinga Newsdesk

PRO
Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.88) by 19.32 percent. This is a 13.41 percent increase over losses of $(0.82) per share

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

Kymera Therapeutics Earnings Review: Q4 Summary

Benzinga Insights

PRO
Kymera Therapeutics Q4 EPS $(0.97) Misses $(0.78) Estimate, Sales $2.871M Miss $14.798M Estimate. Cash And Equivalents Of $1.6B

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.78) by 24.36 percent. This is a 10.23 percent decrease over losses of $(0.88) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved